Cancer therapy
group
Medline
UB
PubMed
Blast
Gene
Therapy Network
Mol.
Biol. Tools
Department
of Biochemistry, School
of Pharmacy, University
of Barcelona.
Av. Diagonal 643, 08028
Barcelona
Phone. (93) 403-4455, Fax: (93) 402-4520,
E-mail :
CCiudad@ub.edu
OBJECTIVES
- To improve already existent cancer
chemotherapy treatments to increase their effectivity.
- To investigate new alternative therapies based
on the new developments in Biochemistry and Molecular Biology.
As a model we use the gene encoding for
Dihydrofolate reductase (DHFR), enzyme that it is widely used as the
target for the chemotherapy that uses methotrexate.
RESEARCH
INTERESTS
- To study the process that develops resistance
to chemotherapy.
- To find modulators of chemotherapy resistance
- To study the transcriptional regulation of the
dhfr gene
- To study the effect of transcription factors,
oncogenes and tumor suppressors on the expression of the dhfr
gene.
- To investigate in detail the regulation of the
transcription factor Sp1 and Sp3
- To explore the postranscriptional regulation
of the DHFR RNA.
- To investigate the role of introns on the
expression of the dhfr gene into protein
- Cloning of genes responsible for the
resistance that arises upon cancer chemotherapy.
- Probing the applicability of antisense
oligonucleotides and siRNA in cancer therapy
- To generate and isolate aptamers for DHFR
protein with the aim to inhibit this
enzyme.
- To design liposomes and immunoliposomes for
introducing oligonucleotides into the cells.
- Identification of target genes involved in the
activation of apoptosis and in the inhibition of angiogenesis: Survivin.
- To study the effect of TFOs (Triplex forming
oligonucleotides) on dhfr transcription
- To repair DNA mutations within the endogenous locus
using TFBOs (Triplex Forming Bifunctional Oligonucleotides) and
Hairpins. Usage of polipurine hairpins against gene expression
- Genomic studies related to Methotrexate
resistance: Arrays and MicroArrays
- Regulation of Methotrexate resistance by
microRNAs
- Networking of differentially expressed genes
in methotrexate resistant cells
RESEARCH
TEAM 
Elisabet
Selga Ph.D. Fellow
Cristina
Almagro Ph.D.
Fellow
SCIENTIFIC
PUBLICATIONS
-

Transcriptional
regulation of the 5'-flanking region of the human transcription factor
Sp3 gene by NF-1, c-Myb, B-Myb, AP-1 and E2F.
Tapias A, Ciudad CJ, Noé V. Biochim
Biophys Acta.
2008 May;
1779(
5):
318-29. <><><>>>>
-

Transcriptional
regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells
resistant to methotrexate: role in the cell cycle and apoptosis.
Selga E, Noé V, Ciudad CJ.
Biochem Pharmacol. 2008 Jan 15;
75(
2):
414-26. Epub 2007 Sep 8.
-

Short-term oleoyl-estrone treatment
affects capacity to manage lipids in rat adipose tissue.
BMC
Genomics. 2007 Aug 28;
8:
292.
-
- Strand
displacement of double-stranded DNA by triplex-forming
antiparallel purine-hairpins. Coma
S, Noe V, Eritja R, Ciudad CJ. Oligonucleotides.
2005 Dec;15(4):269-83.
- Gene
identification by cDNA arrays in HPV-positive cervical cancer. Vazquez-Ortiz
G, Ciudad CJ, Pina P, Vazquez K, Hidalgo A, Alatorre B, Garcia JA,
Salamanca F, Peralta-Rodriguez R, Rangel A, Salcedo M. Arch
Med Res. 2005 Sep-Oct;36(5):448-58
- Anti-migratory
and anti-angiogenic effect of p16: a novel localization
at membrane ruffles and lamellipodia in endothelial cells. Alhaja
E, Adan J, Pagan R, Mitjans F, Cascallo M, Rodriguez M, Noe V, Ciudad
CJ, Mazo A, Vilaro S, Piulats J. Angiogenesis.
2004;7(4):323-33.
- Modulation
of IMPDH2, survivin,
topoisomerase I and vimentin increases
sensitivity to methotrexate in HT29 human colon cancer cells. Penuelas
S, Noe V, Ciudad CJ. FEBS J. 2005 Feb;272(3):696-710.
- Expression profiles of a human
pancreatic
cancer cell line upon induction of apoptosis: Search for modulators in
cancer therapy. Blasco
F, Penuelas S, Cascallo M, Hernandez JL, Alemany C, Masa M, Calbo J,
Soler M, Nicolas M, Perez-Torras S, Gomez A, Tarrason G, Noe V, Mazo A,
Ciudad CJ, Piulats J. Oncology. 2004;67(3-4):277-90.
- Use
of siRNAs and antisense
oligonucleotides against survivin RNA to inhibit steps leading to tumor
angiogenesis.
Coma
S, Noe V, Lavarino C, Adan J, Rivas M, Lopez-Matas M, Pagan R, Mitjans
F, Vilaro S, Piulats J & Ciudad CJ. Oligonucleotides. (2004)
Vol 14: 100-13. (Abstract)
- Rosiglitazone
upregulates caveolin-1
expression in THP-1 cells through a PPAR-dependent mechanism. Llaverias G,
Vazquez-Carrera M, Sanchez RM, Noe V, Ciudad CJ, Laguna JC &
Alegret M. J Lipid Res. (2004) (Abstract) (pdf)
- Atorvastatin
reduces CD68, FABP4, and HBP
expression in oxLDL-treated human macrophages. Llaverias G, Noe V,
Penuelas S,
Vázquez-Carrera M, Sanchez RM, Laguna JC, Ciudad CJ &
Alegret M. Biochem Biophys Res
Commun. (2004) Vol 318 :265-74. (Abstract) (pdf)
- A novel muscle
DNA-binding activity in the GLUT1 promoter.
Sanchez-Feutrie
M, Santalucia T, Fandos C, Noe V, Viñals F, Brand NJ, Ciudad CJ,
Palacin M & Zorzano A. Cell
Mol Life
Sci. (2004) Vol 61: 709-20. (Abstract)
- The
expression of
retinoblastoma
and Sp1 is increased by low concentrations of cyclin-dependent kinase
inhibitors, S. Peñuelas, C. Alemany, V. Noé & C.
Ciudad. European Journal of Biochemistry. (2003) Vol 270: 4809-22 (Abstract) (pdf)
- An intron is
required for dihydrofolate reductase protein stability. V. Noé,
S. MacKenzie & C.J. Ciudad. The Journal of Biological Chemistry.
(2003) Vol
278: 38292-300 (Abstract) (pdf)
- CD4 Expression
Decrease by Antisense Oligonucleotides: Inhibition of Rat T CD4+ Cell
Reactivity. M. Rabanal, A. Franch, V. Noé, C.J. Ciudad, C. Castellote & M.
Castell. Oligonucleotides. (2003) vol 13:217-28.
Abstract
- Transcriptional
regulation of the human
Sp1 gene
promoter by SP-family members, NF-Y and E2F.. Marta Nicolás,
Vèronique Noé, and Carlos J. Ciudad. Biochemical Journal.
(2003) Vol 371:265-75. (Abstract) (pdf)
- Inhibition of cd4 expression
by antisense
oligonucleotides in PMA-treated lymphocytes. M. Rabanal , A. Franch, V.
Noé, C. J. Ciudad , M. Castell & C. Castellote - Antisense
and Nucleic Acid Drug Development. (2002) Vol 12, 399-410 Abstract
- Development and effects of
immunoliposomes
carrying an antisense oligonucleotide against DHFR RNA and directed
toward human breast cancer cells overexpressing HER2. Rodríguez,
M.M., Coma, S., Noé, V., & Ciudad, C.J. Antisense &
Nucleic Acid Drug Development. (2002) Vol 12: 257 - 264 Abstract
- Cloning and characterization
of the
5'-flanking region of the human transcription factor Sp1. Nicolas M,
Noe V, Jensen KB, Ciudad CJ. J Biol Chem. (2001) Vol 276:
22126-22132 (Abstract) (pdf)
- Sp1 involvement in the
4beta-phorbol
12-myristate 13-acetate (TPA)-mediated increase in resistance to
methotrexate in Chinese hamster ovary cells. Noe V V, Alemany C,
Nicolas M, Ciudad CJ. Eur J Biochem. (2001) Vol 268 :3163-3173. (Abstract) (pdf)
- DAG accumulation from
saturated fatty acids
desensitizes insulin stimulation of glucose uptake in muscle cells.
Montell E, Turini M, Marotta M, Roberts M, Noe V, Ciudad CJ, Mace K,
Gomez-Foix AM. Am J Physiol Endocrinol Metab (2001) Vol 280 :E229-E237 (Abstract) (pdf)
- Differential induction of
stearoyl-CoA
desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells.
Rodriguez C, Cabrero A, Roglans N, Adzet T, Sanchez RM, Vazquez M,
Ciudad CJ, Laguna JC. Biochem Pharmacol (2001) Vol 61 :357-364 (Abstract) (pdf)
- Differences in the formation
of
PPARalpha-RXR/acoPPRE complexes between responsive and nonresponsive
species upon fibrate administration. Rodriguez C, Noe V, Cabrero A,
Ciudad CJ, Laguna JC. Mol Pharmacol (2000) Vol 58 :185-93 (Abstract) (pdf)
- Identification by RNA-based
arbitrarily primed
PCR of the involvement of cytochrome c oxidase in the development of
resistance to methotrexate. C. Alemany, V. Noé, and C.J. Ciudad.
Biochim Biophys Acta (2000) Vol 1495 :319-26. (Abstract) (pdf)
- Effects of differential
polyadenylation and
cell growth in dihydrofolate reductase mRNA stability. V Noé,
Ciudad, C.J. & Chasin, L.A.J Biol Chem (1999) Vol 274 :27807-14 (Abstract) (pdf)
- Effects of antisense
oligonucleotides directed
toward dihydrofolate reductase RNA in mammalian cultured cells.
Rodriguez, M., Noé, V., Alemany, C., Miralles, A., Bemi, V.,
Caragol, I. and Ciudad, C.J. Int J Cancer (1999) Vol 81 :785-92 (Abstract) (pdf)
- Retinoblastoma protein
associates with Sp1 and
activate the hamster dihydrofolate reductase promoter. Noé, V.,
Alemany, C., Chasin, L.A. and Ciudad, C.J. Oncogene (1998) Vol 16
:1931-8 (Abstract) (pdf)
- Cell growth regulation of the
hamster
dihydrofolate reductase gene promoter by transcription factor Sp1.
Noé, V., Chen, C., Alemany, C., Nicolás, M., Caragol, I.,
Chasin, L.A., and Ciudad, C.J. Eur J Biochem (1997) Vol 249: 13-20 (Abstract)
- Protein kinase C inhibitors
reduce phorbol
ester-induced resistance to methotrexate in Chinese hamster ovary
cells. Noé-V; Ciudad-CJ. Biochem Pharmacol (1995) Vol 50: 337-46
(Abstract) (pdf)
- Purine enzyme profile in human
colon-carcinoma
cell lines and differential sensitivity to deoxycoformycin and
2'-deoxyadenosine in combination. Camici-M; Turriani-M; Tozzi-MG;
Turchi-G; Cos-J; Alemany-C; Miralles-A; Noé-V; Ciudad-CJ. Int J
Cancer (1995) Vol 62 :176-83 (Abstract)
- Determination of dihydrofolate
reductase gene
amplification from single cell colonies by quantitative polymerase
chain reaction.Noé-V; Alemany-C; Ciudad-CJ. Anal Biochem (1995)
Vol 224 :600-3 (Abstract) (pdf)
- Cytotoxicity of
deoxycoformycin on human colon
carcinoma cell lines.Camici M, Turriani M, Turchi G, Tozzi MG, Cos J,
Alemany C, Noe V, Ciudad CJ. Adv Exp Med Biol (1994) Vol 370: 275-8
- Point mutational analysis of the
hamster
dihydrofolate reductase minimum promoter.Ciudad-CJ; Morris-AE; Jeng-C;
Chasin-LA. J Biol Chem (1992) Vol 267: 3650-6 (Abstract)
- RNA processing mutants at the
dihydrofolate
reductase locus in Chinese hamster ovary cells. v Chasin LA, Urlaub G,
Mitchell P, Ciudad C, Barth J, Carothers AM, Steigerwalt R, Grunberger
D. Prog Clin Biol Res (1990) Vol 340A: 295-304
- Nonsense mutations in the
dihydrofolate
reductase gene affect RNA processing.Urlaub G, Mitchell PJ, Ciudad CJ,
Chasin LA. Mol Cell Biol (1989) Vol 9: 2868-80 (Abstract).
- Deletion analysis of the Chinese
hamster
dihydrofolate reductase gene promoter.Ciudad CJ, Urlaub G, Chasin LA. J
Biol Chem (1988) Vol 263: 16274-82 (Abstract)
COLLABORATION GROUPS
This group is part of the Consolidated Group
"Anticancer,
Antiatherosclerotic and Antiinflammatory
Therapies" together with the Unit of
Pharmacology and the Department
of Physiology from the School of
Pharmacy, University of Barcelona.
Our group forms part of the "Gene
Therapy Network" and "Medical
Chemistry" suported by the Generalitat of Catalonia
At the international level, we maintain a
stable collaboration with the Department
of Biological Sciences.(
Columbia
University) and Molecular
Neuro-Oncology (Rockefeller
University), both in New York City.
RESEARCH PROJECTS
- Differentially expressed Nodes
in Genomic Networks from Methotrexate resistant cells and sensitization
by siRNAs; DHFR: regulation by Sp3, Stability of the protein and Gene
Therapy. Biomedicine (2006-2008)
- Collaborative project with
Merck-Farma regarding knock-out of specific genes with pro-angiogenic
function (2005)
- Genomic profile of methotrexate resistance,
molecular mechanisms of DHFR regulation and gene therapy. CICYT
(2002-2005)
- Collaborative project with Merck-Farma
laboratories related with antiangiogenic targets (2004)
- Fundació Caixa de Pensions 'La Caixa';
Functional and Molecular interaction of the glutamic and adenosine
metabotropic receptors and their role in the Alzheimer disease.
Identification of new targets for the diagnostic and therapy of the
disease. (2002-2005)
- Collaborative project with Nutrexpa
laboratories (2002-2003)
- Cancer Chemotherapy: Resistance and Lipidic
Metabolism. SGR (2002-2005)
- Collaborative project with Merck-Farma
laboratories related with proapoptotic targets (2001-2002)
- Functional genomic study of the effect of
statins and PPAR activators on the gene profile induced by oxidized LDL
in THP-1 cells. FISss (2001-2003)
- Cancer Chemotherapy: Resistance and Lipidic
Metabolism. SGR (2000-2002)
- Targeting of genes and antisense
oligonucleotides by novel liposome formulations: Evaluation of their
therapeutic efficacy in human leukemia. JNIC (2000-2003)
- Collaborative project with Merck-Farma
laboratories (1999-2000)
- Transcriptional and postranscriptional
regulation of DHFR. Inhibition of the protein by oligonucleotides
isolated from combinatorial libraries. CICYT (1999-2002)
- Cancer Chemotherapy: Resistance and Lipidic
Metabolism. SGR (1998)
- Resistance to chemotherapy developed by
methotrexate: Molecular mechanisms and modulators. CICYT (1996)
- Cancer Chemotherapy: Resistance and Lipidic
Metabolism. SGR (1996)
- Cancer Chemotherapy: Resistance and Lipidic
Metabolism. GRQ (1994)
- Cloning of genes responsible for the gene
amplification that develops upon cancer chemotherapy. CICYT (1994)
- Molecular mechanism of action of
deoxycoformycin in tumor cells. CNR (1993)
- Regulation of the dhfr gene promoter
throughout the cell cycle. Relationship with the gene amplification
developed upon methotrexate treatment. FISss (1992)